JP2005532296A5 - - Google Patents

Download PDF

Info

Publication number
JP2005532296A5
JP2005532296A5 JP2003586306A JP2003586306A JP2005532296A5 JP 2005532296 A5 JP2005532296 A5 JP 2005532296A5 JP 2003586306 A JP2003586306 A JP 2003586306A JP 2003586306 A JP2003586306 A JP 2003586306A JP 2005532296 A5 JP2005532296 A5 JP 2005532296A5
Authority
JP
Japan
Prior art keywords
hapten
adjuvant
ligand
host animal
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003586306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005532296A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/011663 external-priority patent/WO2003089593A2/en
Publication of JP2005532296A publication Critical patent/JP2005532296A/ja
Publication of JP2005532296A5 publication Critical patent/JP2005532296A5/ja
Pending legal-status Critical Current

Links

JP2003586306A 2002-04-19 2003-04-16 アジュバントにより増強される免疫療法 Pending JP2005532296A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37381802P 2002-04-19 2002-04-19
PCT/US2003/011663 WO2003089593A2 (en) 2002-04-19 2003-04-16 Adjuvant enhanced immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010157088A Division JP2011012065A (ja) 2002-04-19 2010-07-09 アジュバントにより増強される免疫療法

Publications (2)

Publication Number Publication Date
JP2005532296A JP2005532296A (ja) 2005-10-27
JP2005532296A5 true JP2005532296A5 (enExample) 2006-06-08

Family

ID=29251090

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003586306A Pending JP2005532296A (ja) 2002-04-19 2003-04-16 アジュバントにより増強される免疫療法
JP2010157088A Pending JP2011012065A (ja) 2002-04-19 2010-07-09 アジュバントにより増強される免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010157088A Pending JP2011012065A (ja) 2002-04-19 2010-07-09 アジュバントにより増強される免疫療法

Country Status (12)

Country Link
US (1) US20030198643A1 (enExample)
EP (1) EP1496934A4 (enExample)
JP (2) JP2005532296A (enExample)
CN (1) CN1662251B (enExample)
AR (1) AR039429A1 (enExample)
AU (1) AU2003224989B2 (enExample)
CA (1) CA2482924A1 (enExample)
IL (1) IL164546A0 (enExample)
NZ (1) NZ536609A (enExample)
TW (1) TW200406220A (enExample)
WO (1) WO2003089593A2 (enExample)
ZA (1) ZA200408427B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA005823B1 (ru) * 2000-03-31 2005-06-30 Пердью Рисерч Фаундейшн Способ лечения с использованием конъюгатов лиганд-иммуноген
CN1635910A (zh) 2001-05-02 2005-07-06 普渡研究基金会 巨噬细胞介导的疾病的治疗和诊断
EP1434603B1 (en) * 2001-09-28 2009-12-16 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043603B2 (en) * 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US7745157B2 (en) * 2003-02-21 2010-06-29 University Of Maryland, Baltimore Human lymphocyte medium adjuvant
ATE412897T1 (de) 2003-05-30 2008-11-15 Purdue Research Foundation Diagnoseverfahren für atherosklerose
CN101128152A (zh) * 2004-12-23 2008-02-20 普渡研究基金会 发射正电子段层成像方法
AU2006230219A1 (en) * 2005-03-30 2006-10-05 Endocyte, Inc. Method for cancer prognosis using cellular folate vitamin receptor quantification
CN101355928B (zh) 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
WO2007006041A2 (en) 2005-07-05 2007-01-11 Purdue Research Foundation Imaging and therapeutic method using monocytes
US8715677B2 (en) * 2005-09-01 2014-05-06 Celgene Corporation Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy
EP1940473A2 (en) 2005-09-23 2008-07-09 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
US20070134259A1 (en) * 2005-11-21 2007-06-14 David Bundle Methods and compositions for pharmacologially controlled targeted immunotherapy
WO2007092299A2 (en) * 2006-02-03 2007-08-16 Purdue Research Foundation Targeted conjugates and radiation
CA2663851A1 (en) * 2006-09-26 2008-04-03 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
CA2668197A1 (en) 2006-11-03 2008-05-15 Philip S. Low Ex vivo flow cytometry method and device
JP5869205B2 (ja) 2007-02-07 2016-02-24 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ ポジトロン放射断層画像法
US8961926B2 (en) * 2007-05-25 2015-02-24 Purdue Research Foundation Method of imaging localized infections
US20090012009A1 (en) * 2007-06-01 2009-01-08 Low Philip S Composition and Method for Treating Inflammatory Disease
JP5554713B2 (ja) * 2007-11-15 2014-07-23 エンドサイト，インク． 接合体を投与する方法
CN103961701B (zh) 2013-02-05 2018-09-14 日东电工株式会社 疫苗组合物
EP2970349A4 (en) * 2013-03-15 2017-02-15 Newlink Genetics Corporation Carbohydrate-modified glycoproteins and uses thereof
US10590180B2 (en) 2015-06-19 2020-03-17 National University Corporation Shizuoka University Immune function development promoter and growth promoter
US20210100896A1 (en) * 2017-04-05 2021-04-08 University Of Miami Methods and compositions for stimulating the immune system
CN109061172B (zh) * 2018-09-21 2021-07-06 中国烟草总公司郑州烟草研究院 一种检测仲丁灵的酶联免疫试剂盒及其应用
WO2020200481A1 (en) * 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Treatment involving interleukin-2 (il2) and interferon (ifn)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31252A (en) * 1861-01-29 Improvement in iron ties for cotton-bales
US39583A (en) * 1863-08-18 Improved variable exhaust for locomotives
US2816110A (en) * 1956-11-23 1957-12-10 Merck & Co Inc Methods for the production of substituted pteridines
US4713249A (en) * 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
US4659655A (en) * 1981-11-25 1987-04-21 Bio-Response, Inc. Method for isolating product-producing cells
US5140104A (en) * 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
US5266333A (en) * 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US5062171A (en) * 1986-09-09 1991-11-05 Kinetic Concepts, Inc. Patient support air bags and related system with connectors for detachable mounting of the bags
WO1990009804A1 (en) * 1989-02-24 1990-09-07 The Regents Of The University Of California Genetically engineered immunoglobulins
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
WO1992003569A1 (en) * 1990-08-29 1992-03-05 Centre Hospitalier Regional De Nantes Protein polyligands joined to a stable protein core
US6335434B1 (en) * 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US5159079A (en) * 1991-12-20 1992-10-27 Eli Lilly And Company 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5547668A (en) * 1995-05-05 1996-08-20 The Board Of Trustees Of The University Of Illinois Conjugates of folate anti-effector cell antibodies
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
WO2001047552A1 (en) * 1999-09-08 2001-07-05 Sloane-Kettering Institute For Cancer Research Polysialic acid-klh conjugate vaccine
US20020039583A1 (en) * 1999-09-30 2002-04-04 Subjeck John R. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
EA005823B1 (ru) * 2000-03-31 2005-06-30 Пердью Рисерч Фаундейшн Способ лечения с использованием конъюгатов лиганд-иммуноген
EP1434603B1 (en) * 2001-09-28 2009-12-16 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates

Similar Documents

Publication Publication Date Title
JP2005532296A5 (enExample)
JP2002531421A5 (enExample)
JP2006507265A5 (enExample)
JP2003509349A5 (enExample)
EA200201042A1 (ru) Способ лечения с использованием конъюгатов лиганд-иммуноген
JP2003528924A5 (enExample)
JP2003501474A5 (enExample)
JP2004505047A5 (enExample)
JP2004514663A5 (enExample)
ATE451935T1 (de) Behandlungsverfahren mit liganden- immunogenkonjugaten
JPWO2020022272A5 (enExample)
EP1862458A3 (en) Therapeutic agents useful for treating pain
EA200100610A1 (ru) Конъюгат гаптен-носитель (варианты), антитело и способ его получения, функциональный фрагмент антитела, набор для определения присутствия никотина в образце, вакцинная композиция (варианты) и способ профилактики или лечения никотиновой аддикции (варианты)
WO2004064759A3 (en) Use of tryptanthrin compounds for immune potentiation
EA200200194A1 (ru) Антагонисты хемокинного рецептора и способы их применения
JP2004507465A5 (enExample)
RU2003116059A (ru) Арилэфирзамещенные имидазохинолины
JP2008509187A5 (enExample)
KR960703907A (ko) 퀴놀린 카르복실산 유도체
JP2006506441A5 (enExample)
WO2003089593A3 (en) Adjuvant enhanced immunotherapy
RU2323211C2 (ru) Новые производные бензимидазола, способы их получения, их применение и содержащая их фармацевтическая композиция
JP2003519228A5 (enExample)
JP2008501036A5 (enExample)
JP2002534481A5 (enExample)